Here's how EHOONLINE.BIOMEDCENTRAL.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

EHOONLINE . BIOMEDCENTRAL . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Ehoonline.biomedcentral.com Make Money
  6. How Much Does Ehoonline.biomedcentral.com Make
  7. Keywords
  8. Topics
  9. Schema
  10. Social Networks
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. CDN Services

We are analyzing https://ehoonline.biomedcentral.com/articles/10.1186/s40164-022-00263-4.

Title:
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia | Experimental Hematology & Oncology | Full Text
Description:
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately 30% of MDS eventually progress to AML, associated with increasingly aggressive neoplastic hematopoietic clones and poor survival. Dysregulated immune microenvironment has been recognized as a key pathogenic driver of MDS and AML, causing high rate of intramedullary apoptosis in lower-risk MDS to immunosuppression in higher-risk MDS and AML. Immune checkpoint molecules, including programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), play important roles in oncogenesis by maintaining an immunosuppressive tumor microenvironment. Recently, both molecules have been examined in MDS and AML. Abnormal inflammatory signaling, genetic and/or epigenetic alterations, interactions between cells, and treatment of patients all have been involved in dysregulating PD-1/PD-L1 signaling in these two diseases. Furthermore, with the PD-1/PD-L1 pathway activated in immune microenvironment, the milieu of BM shift to immunosuppressive, contributing to a clonal evolution of blasts. Nevertheless, numerous preclinical studies have suggested a potential response of patients to PD-1/PD-L1 blocker. Current clinical trials employing these drugs in MDS and AML have reported mixed clinical responses. In this paper, we focus on the recent preclinical advances of the PD-1/PD-L1 signaling in MDS and AML, and available and ongoing outcomes of PD-1/PD-L1 inhibitor in patients. We also discuss the novel PD-1/PD-L1 blocker-based immunotherapeutic strategies and challenges, including identifying reliable biomarkers, determining settings, and exploring optimal combination therapies.
Website Age:
25 years and 11 months (reg. 1999-08-06).

Matching Content Categories {πŸ“š}

  • Science
  • Education
  • Health & Fitness

Content Management System {πŸ“}

What CMS is ehoonline.biomedcentral.com built with?

Custom-built

No common CMS systems were detected on Ehoonline.biomedcentral.com, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of ehoonline.biomedcentral.com audience?

πŸš„ Respectable Traffic: 10k - 20k visitors per month


Based on our best estimate, this website will receive around 12,715 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Ehoonline.biomedcentral.com Make Money? {πŸ’Έ}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (3)
yourbow.com, google.com, doceree.com

How Much Does Ehoonline.biomedcentral.com Make? {πŸ’°}


Display Ads {🎯}

$220 per month
Our estimates place Ehoonline.biomedcentral.com's monthly online earnings from display ads at $149 to $409.

Keywords {πŸ”}

pubmed, article, google, scholar, cells, patients, pdl, cas, central, aml, pdpdl, mds, cell, immune, leukemia, mdsaml, myelodysplastic, expression, myeloid, blood, acute, cancer, signaling, blasts, studies, response, levels, syndrome, nct, tumor, clinical, increased, phase, oncol, zhang, syndromes, combination, inhibitor, found, upregulation, hematol, including, reported, blocker, disease, study, treatment, higher, trial, checkpoint,

Topics {βœ’οΈ}

programmed death ligand-1 pd-1/pd-l1 blocker-based treatment pd-1/pd-l1 blockade-based therapy anti-pd-l1 antibody mpdl3280a combining pd-1/pd-l1 blocker springer nature receptor pd-l1/pd-l2 found dysregulating pd-1/pd-l1 signaling pd-1/pd-l1 antibodies prevents akt/mtor/hif-1Ξ± axis targeting pd-1/pd-l1 pathway aberrant pd-1/pd-l1 signaling dysregulated pd-1/pd-l1 signaling anti pd-1/pd-l1 immunotherapy cd274/jnk/cyclin d2 signaling interferon-Ξ³-dependent inflammatory signature regulating pd-1/pd-l1 expression anti-pd-1/pd-l1 therapy dysregulated pd-1/pd-l1 pathway aberrant pd-1/pd-l1 expression increased pd-1/pd-l1 signaling availability pd-1/pd-l1 signaling regulation pd-1/pd-l1 pathway activated upregulated pd-1/pd-l1 levels pd-1/pd-l1 inhibition therapy pd-l1 deletion resulted pd-1/pd-l1 inhibitor examined t-cell immunoglobulin mucin-3 anti-pd-l1 antibody pd-1/pd-l1 blocker pd-1/pd-l1 blocker [58 pd-1/pd-l1 blocker [62] pd-1/pd-l1 blocker [107 pd-1/pd-l1 blocker [157 induced cell death overcome interferon-mediated cytotoxicity regulate pd-l1 expression program death-1 signaling hypomethylating agent therapy stem cell-specific mechanism cell death dis hypomethylating agent treatment mds/aml transformation [4 pd-1/pd-l1 blockade pd-1/pd-l1 signaling suppressing pd-l1 expression hypomethylating agent failure pd-1/pd-l1 dysregulation monitoring immune-checkpoint blockade

Schema {πŸ—ΊοΈ}

WebPage:
      mainEntity:
         headline:Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
         description:Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately 30% of MDS eventually progress to AML, associated with increasingly aggressive neoplastic hematopoietic clones and poor survival. Dysregulated immune microenvironment has been recognized as a key pathogenic driver of MDS and AML, causing high rate of intramedullary apoptosis in lower-risk MDS to immunosuppression in higher-risk MDS and AML. Immune checkpoint molecules, including programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), play important roles in oncogenesis by maintaining an immunosuppressive tumor microenvironment. Recently, both molecules have been examined in MDS and AML. Abnormal inflammatory signaling, genetic and/or epigenetic alterations, interactions between cells, and treatment of patients all have been involved in dysregulating PD-1/PD-L1 signaling in these two diseases. Furthermore, with the PD-1/PD-L1 pathway activated in immune microenvironment, the milieu of BM shift to immunosuppressive, contributing to a clonal evolution of blasts. Nevertheless, numerous preclinical studies have suggested a potential response of patients to PD-1/PD-L1 blocker. Current clinical trials employing these drugs in MDS and AML have reported mixed clinical responses. In this paper, we focus on the recent preclinical advances of the PD-1/PD-L1 signaling in MDS and AML, and available and ongoing outcomes of PD-1/PD-L1 inhibitor in patients. We also discuss the novel PD-1/PD-L1 blocker-based immunotherapeutic strategies and challenges, including identifying reliable biomarkers, determining settings, and exploring optimal combination therapies.
         datePublished:2022-03-02T00:00:00Z
         dateModified:2022-03-02T00:00:00Z
         pageStart:1
         pageEnd:21
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s40164-022-00263-4
         keywords:
            Myelodysplastic syndrome
            Acute myeloid leukemia
            Programmed cell death-1
            Programmed cell death ligand-1
            Immune checkpoint
            Hypomethylating agent
            AML transformation
            Hematology
            Oncology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40164-022-00263-4/MediaObjects/40164_2022_263_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40164-022-00263-4/MediaObjects/40164_2022_263_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40164-022-00263-4/MediaObjects/40164_2022_263_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40164-022-00263-4/MediaObjects/40164_2022_263_Fig4_HTML.png
         isPartOf:
            name:Experimental Hematology & Oncology
            issn:
               2162-3619
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Xingcheng Yang
               affiliation:
                     name:Huazhong University of Science and Technology
                     address:
                        name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
                        type:PostalAddress
                     type:Organization
                     name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
                     address:
                        name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ling Ma
               affiliation:
                     name:Huazhong University of Science and Technology
                     address:
                        name:Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xiaoying Zhang
               affiliation:
                     name:Huazhong University of Science and Technology
                     address:
                        name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
                        type:PostalAddress
                     type:Organization
                     name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
                     address:
                        name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Liang Huang
               affiliation:
                     name:Huazhong University of Science and Technology
                     address:
                        name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
                        type:PostalAddress
                     type:Organization
                     name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
                     address:
                        name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Jia Wei
               url:http://orcid.org/0000-0002-6435-9368
               affiliation:
                     name:Huazhong University of Science and Technology
                     address:
                        name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
                        type:PostalAddress
                     type:Organization
                     name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
                     address:
                        name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
      description:Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately 30% of MDS eventually progress to AML, associated with increasingly aggressive neoplastic hematopoietic clones and poor survival. Dysregulated immune microenvironment has been recognized as a key pathogenic driver of MDS and AML, causing high rate of intramedullary apoptosis in lower-risk MDS to immunosuppression in higher-risk MDS and AML. Immune checkpoint molecules, including programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), play important roles in oncogenesis by maintaining an immunosuppressive tumor microenvironment. Recently, both molecules have been examined in MDS and AML. Abnormal inflammatory signaling, genetic and/or epigenetic alterations, interactions between cells, and treatment of patients all have been involved in dysregulating PD-1/PD-L1 signaling in these two diseases. Furthermore, with the PD-1/PD-L1 pathway activated in immune microenvironment, the milieu of BM shift to immunosuppressive, contributing to a clonal evolution of blasts. Nevertheless, numerous preclinical studies have suggested a potential response of patients to PD-1/PD-L1 blocker. Current clinical trials employing these drugs in MDS and AML have reported mixed clinical responses. In this paper, we focus on the recent preclinical advances of the PD-1/PD-L1 signaling in MDS and AML, and available and ongoing outcomes of PD-1/PD-L1 inhibitor in patients. We also discuss the novel PD-1/PD-L1 blocker-based immunotherapeutic strategies and challenges, including identifying reliable biomarkers, determining settings, and exploring optimal combination therapies.
      datePublished:2022-03-02T00:00:00Z
      dateModified:2022-03-02T00:00:00Z
      pageStart:1
      pageEnd:21
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s40164-022-00263-4
      keywords:
         Myelodysplastic syndrome
         Acute myeloid leukemia
         Programmed cell death-1
         Programmed cell death ligand-1
         Immune checkpoint
         Hypomethylating agent
         AML transformation
         Hematology
         Oncology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40164-022-00263-4/MediaObjects/40164_2022_263_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40164-022-00263-4/MediaObjects/40164_2022_263_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40164-022-00263-4/MediaObjects/40164_2022_263_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40164-022-00263-4/MediaObjects/40164_2022_263_Fig4_HTML.png
      isPartOf:
         name:Experimental Hematology & Oncology
         issn:
            2162-3619
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Xingcheng Yang
            affiliation:
                  name:Huazhong University of Science and Technology
                  address:
                     name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
                     type:PostalAddress
                  type:Organization
                  name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
                  address:
                     name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ling Ma
            affiliation:
                  name:Huazhong University of Science and Technology
                  address:
                     name:Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xiaoying Zhang
            affiliation:
                  name:Huazhong University of Science and Technology
                  address:
                     name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
                     type:PostalAddress
                  type:Organization
                  name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
                  address:
                     name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Liang Huang
            affiliation:
                  name:Huazhong University of Science and Technology
                  address:
                     name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
                     type:PostalAddress
                  type:Organization
                  name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
                  address:
                     name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Jia Wei
            url:http://orcid.org/0000-0002-6435-9368
            affiliation:
                  name:Huazhong University of Science and Technology
                  address:
                     name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
                     type:PostalAddress
                  type:Organization
                  name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
                  address:
                     name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Experimental Hematology & Oncology
      issn:
         2162-3619
      volumeNumber:11
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Huazhong University of Science and Technology
      address:
         name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
         type:PostalAddress
      name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
      address:
         name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
         type:PostalAddress
      name:Huazhong University of Science and Technology
      address:
         name:Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
         type:PostalAddress
      name:Huazhong University of Science and Technology
      address:
         name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
         type:PostalAddress
      name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
      address:
         name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
         type:PostalAddress
      name:Huazhong University of Science and Technology
      address:
         name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
         type:PostalAddress
      name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
      address:
         name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
         type:PostalAddress
      name:Huazhong University of Science and Technology
      address:
         name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
         type:PostalAddress
      name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
      address:
         name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Xingcheng Yang
      affiliation:
            name:Huazhong University of Science and Technology
            address:
               name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
               type:PostalAddress
            type:Organization
            name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
            address:
               name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
               type:PostalAddress
            type:Organization
      name:Ling Ma
      affiliation:
            name:Huazhong University of Science and Technology
            address:
               name:Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
               type:PostalAddress
            type:Organization
      name:Xiaoying Zhang
      affiliation:
            name:Huazhong University of Science and Technology
            address:
               name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
               type:PostalAddress
            type:Organization
            name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
            address:
               name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
               type:PostalAddress
            type:Organization
      name:Liang Huang
      affiliation:
            name:Huazhong University of Science and Technology
            address:
               name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
               type:PostalAddress
            type:Organization
            name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
            address:
               name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Jia Wei
      url:http://orcid.org/0000-0002-6435-9368
      affiliation:
            name:Huazhong University of Science and Technology
            address:
               name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
               type:PostalAddress
            type:Organization
            name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province
            address:
               name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
      name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
      name:Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
      name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
      name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
      name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
      name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
      name:Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
      name:Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China

External Links {πŸ”—}(651)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Prism.js

CDN Services {πŸ“¦}

  • Crossref

4.86s.